Two Leishmania infantum mimotopes (B10 and C01) identified by phage display showed to
be antigenic and immunogenic for visceral (VL) and tegumentary (TL) leishmaniasis; …

Visceral leishmaniasis (VL) is a clinical form of leishmaniasis with high mortality rates when
not treated. Diagnosis suffers from invasive techniques and sub-optimal sensitivities. The …

The measures for leishmaniasis control include the precise diagnosis of disease. However,
although several recombinant antigens have been tested with this biotechnological purpose …

In this study, a Leishmania hypothetical protein, LiHyS, was evaluated regarding its
antigenicity, immunogenicity and protective efficacy against visceral leishmaniasis (VL) …

An effective therapeutic vaccination strategy is required for controlling visceral leishmaniasis
(VL), a fatal systemic disease, through boosting the immunosuppressed state in Leishmania …

Aims Leishmaniasis, caused by the protozoan parasite poses a significant health burden
globally. With a very few specific drugs, increased drug resistance it is important to look for …

Visceral leishmaniasis (VL) is caused by Leishmania infantum in the Mediterranean basin
and affects primarily children and immunosuppressed individuals. Various strategies of …

Background Visceral leishmaniasis (VL), is a parasitic disease that causes serious medical
consequences if treatment is delayed. Despite a decline in the number of VL cases in the …

The most dangerous form of leishmaniasis is Visceral leishmaniasis (VL). The elimination of
VL depends not only on agent treatments but also on effective vaccines against Leishmania …

Cell-penetrating peptides have been extensively utilized for the purpose of facilitating the
intracellular delivery of cargo that is impermeable to the cell membrane. The researchers …